Abstract Number: 506 • 2015 ACR/ARHP Annual Meeting
Evaluation of Persistence and Outcomes in Patients Treated with TNF and Non-TNF Biologics Following Treatment Clinical Pathway in Rheumatoid Arthritis
Background/Purpose: Use of biologic agents for the treatment of rheumatoid arthritis continues to grow rapidly, with the cost of these agents putting a significant strain…Abstract Number: 507 • 2015 ACR/ARHP Annual Meeting
Meta-Analysis of the Time Course of the Response to Adalimumab Plus Methotrexate or Methotrexate Monotherapy in Clinical Trials of Patients with Rheumatoid Arthritis
Background/Purpose: Adalimumab (ADA) plus methotrexate (MTX) and MTX treatments for rheumatoid arthritis (RA) have been assessed in phase 2–4 clinical trials. This meta-analysis used 5…Abstract Number: 508 • 2015 ACR/ARHP Annual Meeting
Impact of Race on Patient Global Scores and the Misclassification of Disease Activity
Background/Purpose: Disease activity measurement is a cornerstone of the Treat to Target strategy. However, all currently used measures include a Patient Global Score (PtGLB )…Abstract Number: 509 • 2015 ACR/ARHP Annual Meeting
In Early Undifferentiated Polyarthritis, 14-3-3η Seroreversion or Sustained Negativity Is Associated with Better Radiographic Outcomes, Even in DAS-28 Remitters
Background/Purpose: Advancements in RA treatment approaches with DMARDs and biological agents have enabled disease remission goals that were previously considered unattainable. The concept of "tight…Abstract Number: 510 • 2015 ACR/ARHP Annual Meeting
Histologic Scoring of Arthroplasty Synovial Samples May Predict RA Flare
Background/Purpose: Patients with established RA undergoing total joint arthroplasty (TJA) frequently experience a disease flare within 6 weeks of surgery. This study aims to determine…Abstract Number: 511 • 2015 ACR/ARHP Annual Meeting
Pretreatment Prediction of Response to Anti-Cytokine Therapy Using Serum Cytokine/Chemokine/Soluble Receptors in Individual Rheumatoid Arthritis Patient
Background/Purpose: In clinical practice in rheumatoid arthritis (RA), it has been noted that each anti-rheumatic therapy delivers a different outcome for individual RA patients and…Abstract Number: 512 • 2015 ACR/ARHP Annual Meeting
Physical Function and Inflammatory Activity in Rheumatoid Arthritis Patients. Is Disease Duration Important?
Background/Purpose: HAQ (Health Assessment Questionnaire) assesses functional disability in rheumatoid arthritis (RA) patients. Correlation between HAQ and disease activity might change according to the length…Abstract Number: 513 • 2015 ACR/ARHP Annual Meeting
Cumulative Association of Genetic Variants with Rheumatoid Joint Damage Progression in Mexican Americans and European Americans
Background/Purpose: Genealogical and genetic association studies have suggested that joint damage in rheumatoid arthritis (RA) may be heritable. We and others have found a number…Abstract Number: 514 • 2015 ACR/ARHP Annual Meeting
MRI Bone Oedema at Enrollment Predicts the Development of Rapid Radiographic Progression at 1 Year Toward Patients with Early-Stage Rheumatoid Arthritis: Results from Nagasaki University Early Arthritis Cohort
Background/Purpose: To clarify whether MRI bone oedema predicts the development of rapid radiographic progression (RRP) in Nagasaki University Early Arthritis Cohort patients with early-stage rheumatoid…Abstract Number: 515 • 2015 ACR/ARHP Annual Meeting
Are Changes in Autoantibody Levels Reflecting Change in Prognosis of Rheumatoid Arthritis?
Background/Purpose: The presence of rheumatoid factor (RF) and antibodies against citrullinated peptides (ACPA) is associated with progression of joint damage in patients with rheumatoid arthritis…Abstract Number: 516 • 2015 ACR/ARHP Annual Meeting
Immunological and Ultrasound Characteristics of Patients with Rheumatoid Arthritis in Clinical Remission – Can We Use These to Predict Outcomes?
Background/Purpose: Remission is the key treatment goal in rheumatoid arthritis (RA). Although clinical remission is increasingly achieved, many patients progress both structurally and functionally. We…Abstract Number: 517 • 2015 ACR/ARHP Annual Meeting
Investigating Psychological Predictors of Biologic Treatment Response in Patients with Severe Active Rheumatoid Arthritis
Background/Purpose: Biologic therapy is now a cornerstone of RA management, but treatment response is variable, failing in up to 40% of patients. To direct appropriate…Abstract Number: 518 • 2015 ACR/ARHP Annual Meeting
Antibody Responses to Citrullinated Porphyromonas Gingivalis Peptidylarginine Deiminase: Associations with Disease Risk Factors and Severity in Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is characterized by autoimmunity to citrullinated proteins. Porphyromonas gingivalis (Pg) has been proposed as an epidemiologic link between RA and periodontitis…Abstract Number: 519 • 2015 ACR/ARHP Annual Meeting
In Indigenous North Americans at High Risk for RA Complement C5 Level Is Associated with ACPA Positivity and C5a with Transition to Synovitis Even after Correcting for in Vitro Complement Activation Found with Prolonged Sample Storage
Background/Purpose: Complement activation, a key component of innate immunity and activator of adaptive immunity has been linked to RA pathogenesis. Anti-citrullinated peptide antibody (ACPA) and…Abstract Number: 520 • 2015 ACR/ARHP Annual Meeting
Antibody to Porphyromonas Gingivalis in Pre-Clinical Rheumatoid Arthritis
Background/Purpose: Periodontitis (PD) has been implicated as an etiologic risk factor in rheumatoid arthritis (RA), an association that is speculated to be related to the…
ACR Meeting Abstracts